貝瑞基因(000710.SZ)及君聯致成、啟明融新合計以2億元認購福建和瑞新增註冊資本
格隆匯 10 月 12日丨貝瑞基因(000710.SZ)公佈，2020年10月12日，貝瑞基因、珠海君聯致成股權投資合夥企業(有限合夥)(“君聯致成”)、北京啟明融新股權投資合夥企業(有限合夥)(“啟明融新”)與福建和瑞簽訂了《有關福建和瑞基因科技有限公司之增資協議》、《有關福建和瑞基因科技有限公司之股東協議》。
上述協議約定貝瑞基因、君聯致成、啟明融新合計以人民幣2億元認購福建和瑞人民幣677.5281萬元新增註冊資本，對應本輪投資完成後共計9.09%福建和瑞股權(“A+輪投資”)。
此次交易完成後，預計貝瑞基因及福建和瑞將根據A輪投資時簽署的《經銷協議》銷售、推廣對方與腫瘤業務相關產品及服務，貝瑞基因將與福建和瑞之間產生銷售及/或採購腫瘤業務相關產品及服務的日常關聯交易。如若發生相關交易，貝瑞基因將根據上市規則等相關規定履行信息披露義務。
福建和瑞於2020年8月推出自主知識產權的首個肝癌早篩產品-萊思寧(Liver Screening)後，已加速其他多癌種的早篩早診項目研發。此次交易的投資款將繼續用於福建和瑞腫瘤早診的研發投入以及其他腫瘤業務的經營性投入，將避免未來腫瘤業務大量研發投入及較長落地週期產生的潛在風險及對貝瑞基因產生的不利影響；
此次交易完成後，福建和瑞將仍為貝瑞基因的參股子公司，貝瑞基因將有權委派兩名董事，本次交易未改變公司在福建和瑞的其他權利義務。此次交易完成後，公司將向福建和瑞履行實繳出資義務，福建和瑞將繼續獲得發展腫瘤業務的資金保障，將繼續增強福建和瑞腫瘤業務研發實力，加強公司在腫瘤領域的業務佈局。
同時，公司及福建和瑞未對福建和瑞投資人承諾業績或保底收益，公司有權在股權收購期間按照前述協議約定的股權收購價格分別購買福建和瑞A輪投資股東持有的福建和瑞股權。因此，公司將在風險可控的條件下享受福建和瑞未來發展的收益，有利於保護中小股東的利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
